SurModics and Edge Therapeutics team up to develop sustained-release, site-specific
neurological to fend off complications after subarachnoid hemorrhage
Dr. James L. Sherley and Dr. Theresa Deisher share their thoughts about
embryonic stem cell research and why they oppose President Obama's order to reinstate federal funding for eSC work
1000 Genomes Project publishes analysis of pilot-phase work
and prepares to launch next steps with help of companies like Affymetrix, Illumina, Life Technologies and 454 Life Sciences
Out of all of our print and
online news coverage, we have picked five stories that we feel illustrate some high points and show how ddn is unique in reporting industry news
We analytical chemists continue to have a
variety of concerns about what we do, and those concerns vary with the context of where we do it. The argument stems from confusion over the worthiness of
providing a service and whether that can ever fit our definition of science.
The most powerful
advance in genomics of the last five years has taken place in DNA sequencing technology. Capillary and gel-based Sanger sequencing has been superseded by new
massively parallel approaches that offer several orders of magnitude greater sequencing capacity, at >500-fold reduction in cost per base.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.